Reported outcomes from medical homes must be able to discern between true and preceived cost savings, and North Carolina is an example of what can go wrong
Yet healthcare expenses continue to rise. How can this be? The savings claimed for these initiatives are illusory, but usually all that is lost is the cost of the initiative itself.
Not so with patient-centered medical homes. Medical homes are the first innovation whose cost is high and whose implementation actually can increase costs far beyond the program itself. This is exactly what happened in the Community Care of North Carolina Medicaid medical home program.
REALITY CHECK
No one applied a "plausibility check" to curious findings of savings-findings at odds with common sense:
What could explain the difference between the actual results and the report? Actuaries rely heavily on trend assumptions, changes in which can swing outcomes. A journal article from the actuary indicates that "choice of trend has a large impact on savings." A valid analysis requires an understanding that trend is not a "choice."
A specific level of savings was achieved, and it's up to the evaluator to find it. Reliance on variables that depend on personal choice automatically invalidates any result, as any outcomes-numerate analyst knows.
Meanwhile, if initiatives and access decisions on this scale continue to be considered generally, the entire healthcare sector needs to learn how to analyze reported outcomes more critically in order to distinguish true cost savings from fallacious results.
DC Roundtable: Patrick Cooney of The Federal Group Drops the Latest on PBM Legislation in Washington
April 11th 2024In this episode of "DC Roundtable," Peter Wehrwein, managing editor of Managed Healthcare Executive, spoke with Patrick Cooney, president of The Federal Group, a lobbying and strategic planning firm in Washington, D.C., about recent developments in Washington concerning PBMs.
Listen
The Relationship Between ILD and MDA5 Antibody-Positive DM
May 2nd 2024Rapidly progressing interstitial lung disease in anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis (DM) is known for its high death rate because it worsens quickly and causes breathing difficulties within three months of initial lung symptoms. However, there isn't much information about the timing between the diagnosis of ILD and MDA5 antibody-positive DM because most research focuses on either the frequency or the death rates rather than the timing of onset.
Read More